ExeVir wins backing to develop llama-derived antibodies for COVID-19
Belgian firm ExeVir Bio has closed on a 23 million euro ($26.9 million U.S.) series A financing round to support the development of its llama-derived antibody technology in treating COVID-19. Read More
Cerevel, Cyclica partner on AI-based drug discovery
Cerevel Therapeutics and Cyclica have announced a research collaboration that will use artificial intelligence (AI) to develop new neurological medicines. Read More
Carisma advances macrophage immunotherapy
Carisma Therapeutics' engineered macrophage immunotherapy has cleared an investigational new drug application through the U.S. Food and Drug Administration. The company intends to initiate a phase I clinical trial for the candidate this year. Read More
Amyris partners with IDRI on scalable vaccine platform
Amyris and the Infectious Disease Research Institute (IDRI) have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology platform. Read More
Cel-Sci reports positive early results with COVID-19 LEAPS conjugate
Cel-Sci completed animal testing using its Ligand Epitope Antigen Presentation System (LEAPS) COVID-19 conjugate, which means the firm can now move into animal challenge studies with the live SARS-CoV-2 virus. Read More
Exonbio launches SARS-CoV-2 rabbit mAbs
Exonbio debuted its SARS-CoV-2 nucleocapsid recombinant monoclonal antibodies for the global in vitro diagnostics and research communities. Read More
Novavax, Fujifilm begin large-scale manufacturing of COVID-19 vaccine
Novavax and Fujifilm Diosynth have signed an agreement covering the bulk manufacture of Novavax's COVID-19 vaccine candidate, NVX-CoV2373, at Fujifilm's Morrisville, NC, facility. Read More
New tools rapidly detect anti-SARS-CoV-2 antibodies
New tools using surrogate viruses may be useful for rapid testing to determine whether antibodies effectively neutralize SARS-CoV-2. The viral vector-based platform approach was published in the Journal of Experimental Medicine on July 21. Read More
Thermo Fisher posts 10% growth in Q2
Thermo Fisher Scientific reported financial results for the second quarter, noting 10% revenue growth. Read More
Replicating RNA COVID-19 vaccine shows robust responses in early testing
A replicating RNA vaccine delivered with a lipid-based nanoparticle emulsion has been shown to produce potent antibodies against SARS-CoV-2 in mice and primates with a single immunization, according to a study published in Science Translational Medicine on July 20. Read More
Conferences
BioTech Pharma Summit
September 27-28
Porto Portugal
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter